L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. - Wikidata - wikimedia - TriplyDB

L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer.

L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer.

http://www.wikidata.org/entity/Q34914565

about

High levels of aromatic amino acids in gastric juice during the early stages of gastric cancer progression Current status of biomarkers for prostate cancer The role of L-type amino acid transporter 1 in human tumors Integrins in the Spotlight of Cancer Genomic profiling of tumor initiating prostatospheres.Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer Prognostic significance of amino-acid transporter expression (LAT1, ASCT2, and xCT) in surgically resected tongue cancer.Correlation between positron emission tomography findings and glucose transporter 1, 3 and L-type amino acid transporter 1 mRNA expression in primary central nervous system lymphomas Gene expression changes with age in skin, adipose tissue, blood and brain.Monoterpene glycoside ESK246 from Pittosporum targets LAT3 amino acid transport and prostate cancer cell growth.Relation of LAT1/4F2hc expression with pathological grade, proliferation and angiogenesis in human gliomas.Synthesis and evaluation of amino acid-based radiotracer 99mTc-N4-AMT for breast cancer imaging.High expression of L-type amino acid transporter 1 as a prognostic marker in bile duct adenocarcinomas Imaging the L-type amino acid transporter-1 (LAT1) with Zr-89 immunoPET Increased expression of system large amino acid transporter (LAT)-1 mRNA is associated with invasive potential and unfavorable prognosis of human clear cell renal cell carcinoma.Relationship between CD147 and expression of amino acid transporters (LAT1 and ASCT2) in patients with pancreatic cancer.Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myeloma L-type amino acid transport and cancer: targeting the mTORC1 pathway to inhibit neoplasia.Analysis of L-type amino acid transporter in canine hepatocellular carcinoma.MicroRNA profiling of the pubertal mouse mammary gland identifies miR-184 as a candidate breast tumour suppressor gene miR-126-3p Inhibits Thyroid Cancer Cell Growth and Metastasis, and Is Associated with Aggressive Thyroid Cancer.Clinical significance of coexpression of L-type amino acid transporter 1 (LAT1) and ASC amino acid transporter 2 (ASCT2) in lung adenocarcinoma Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in patients with ovarian tumors.Study of LAT1 Expression in Brain Metastases: Towards a Better Understanding of the Results of Positron Emission Tomography Using Amino Acid Tracers.Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer Synthesis and evaluation of 18F labeled alanine derivatives as potential tumor imaging agents Characterization of primary prostate carcinoma by anti-1-amino-2-[(18)F] -fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F] FACBC) uptake High Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: proposal of a logistic model for prediction.SLC Transporters: Structure, Function, and Drug Discovery.Efficacy of system l amino acid transporter 1 inhibition as a therapeutic target in esophageal squamous cell carcinoma.Biological significance of fluorine-18-α-methyltyrosine (FAMT) uptake on PET in patients with oesophageal cancer.ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer.L-type amino acid transporter 1 expression is highly correlated with Gleason score in prostate cancer.The impact of L-type amino acid transporter 1 (LAT1) in human hepatocellular carcinoma.Targeting L-type amino acid transporter 1 for anticancer therapy: clinical impact from diagnostics to therapeutics.Prostate Cancer Cells in Different Androgen Receptor Status Employ Different Leucine Transporters.Hypoxia and cellular metabolism in tumour pathophysiology.miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression.PET Tracers Beyond FDG in Prostate Cancer.Suppression of amino acid transporter LAT3 expression on proliferation of K562 cells.

P2860

Q21133895-935C00D9-E9A7-4AB2-8905-D67522D33CFE Q24600574-0D31BB4E-E82D-4F88-83DE-471846077018 Q26775785-1BC29FA8-CFC1-4779-B552-11E26A0D845E Q28066805-CBB3C95E-1D8A-4793-BDD0-F0D6C4E493F0 Q33586722-EC254DB5-2C9C-4F7B-A9CA-E62E951C35F1 Q33592952-63DF13D6-5DCE-4445-AA64-BFD292CF5464 Q33613632-435CC9EE-DB04-4CEC-A2D4-F139E79E5D3D Q33733797-885FEEF8-8944-40F2-B4FE-08979811D96A Q33742819-6DDEF4D4-26A7-4955-9C4A-DCEEAB3BBC31 Q33797210-77CA4D2C-267A-4161-B10A-6247E05C8F81 Q34175221-32B0CA99-ECD0-4471-936B-E5F903809DD0 Q34896422-8D5285A2-BDC2-45AF-9556-28EE13A29A0B Q34998503-0E3B6EE5-8203-4A98-876B-A40074927024 Q35021768-92693C64-A0EE-4061-ACE7-90BEF6EAFCCB Q35028079-BE3937B4-59DF-4EE4-B663-C31B827CA4C7 Q35440166-3A705A6E-D368-484B-AED4-F78613C71AEB Q35713446-27F5F06A-ACCE-477B-BF8E-5C90198CF77F Q35757977-533A392C-A8ED-49DC-BE16-2CACBEBB81E4 Q35774573-081B170D-B5C2-47F4-B74A-8CEFD16A84ED Q35857671-09113BB2-24E8-41EF-8977-CEC653E84F24 Q35921263-F5433399-9195-42D9-BC9C-BAC5BD309F7E Q35941321-E95BD769-4C59-4BE3-BC6C-B07553CD96C6 Q35941337-C6A7CEC2-732D-4939-8BC3-34CF41E303CE Q36045175-4C16B871-0FF3-4A78-AF8B-4D45A52A9C04 Q36166827-AA02D230-AA6D-4899-B7B2-0479BEFAA43B Q36205180-A8C5CFF6-5F5D-4575-8344-B023A137C3C8 Q36533826-E6169712-CC46-4262-9DFB-7D0BDF3ECFBE Q37269734-AC470B59-0305-464D-BEF6-632DEE79336A Q37279747-E7AC9A38-33C1-48FF-99C0-06B34C6AF5EF Q37375216-DFB49DB1-B982-4028-A511-0FC98367783B Q37711666-6A08B2FC-83E2-4DBA-AB38-ED88853CA47A Q37711691-C3EE6523-7E86-4408-9121-55CC87ED26A0 Q38292729-E61BF519-E8FD-43B7-B591-72FC4D5ED5FC Q38396468-6532173E-8CEF-4013-B114-A2CB6D14C68B Q38476583-83CD4E2A-3D76-4E44-B4D1-66984AD8CF77 Q38742764-90F1E6EA-B402-4145-A441-2BFFEEBB81A8 Q38772023-5AB6AFBC-2832-4E38-B0A9-4CA12C093060 Q38972595-A209CB8C-ED8C-4911-95DD-9EAE67CCD9E1 Q39003086-4FE1DA69-A27A-4DB4-9DC2-AD734B4A2790 Q39076144-B08684A6-C4D0-4A87-B420-F6144227D626

P2860

L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer.

http://www.wikidata.org/entity/Q34914565

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

L-type amino-acid transporter ...... malignancy in prostate cancer.

@ast

L-type amino-acid transporter ...... malignancy in prostate cancer.

@en

L-type amino-acid transporter ...... malignancy in prostate cancer.

@nl

type

label

L-type amino-acid transporter ...... malignancy in prostate cancer.

@ast

L-type amino-acid transporter ...... malignancy in prostate cancer.

@en

L-type amino-acid transporter ...... malignancy in prostate cancer.

@nl

prefLabel

L-type amino-acid transporter ...... malignancy in prostate cancer.

@ast

L-type amino-acid transporter ...... malignancy in prostate cancer.

@en

L-type amino-acid transporter ...... malignancy in prostate cancer.

@nl

P1433

Q34914565-47EFDA86-CFB7-41EE-9410-8F09C51705BD

P1476

Q34914565-A7757219-A1BA-4C69-BC3E-E01202BD105D

P2093

Q34914565-272C8347-1BD8-4586-A5BB-BF96CBEFE97B

Q34914565-275485DF-6161-4584-91AE-E4AB8CD161DF

Q34914565-2D31B089-FD8C-42B9-BB64-DD4B449638A6

Q34914565-4451B214-5F27-45F7-B09E-742FFF77EAFC

Q34914565-9ADF7801-B688-4F58-964F-A46ABC9AB9C0

Q34914565-A77E7F15-E5E6-4727-B50F-622186AE0E0D

Q34914565-AF3C73A2-FEA3-46B6-A015-8785C2634781

Q34914565-CC01A630-6112-4D1F-8A94-5BE8E9E98091

Q34914565-E1E672C0-C9BE-46FD-A185-62510BB41764

Q34914565-EF0C43E3-B22F-4160-A85F-6F4843BCE34C

P2860

Q34914565-0ACA87E7-6286-4C1D-A0E4-08673B683663

P304

Q34914565-C90E721E-414A-4422-A317-29FD17AF91A3

P31

Q34914565-5CD14354-11BA-4FCB-86C3-0BE6305EABB5

P356

Q34914565-55F270E0-AE55-477B-B8EA-2FE4656DADBF

P433

Q34914565-E7DB8657-27EE-4D7A-AF2B-C41ED7B5A20E

P478

Q34914565-A52887E6-C60E-4841-A488-3C78095B4AC5

P577

Q34914565-2F9E5A79-2DBD-4BCF-A941-849FD85D2F51

P698

Q34914565-111FB6AE-C74C-444B-B20A-35C29ACCE9CB

P921

Q34914565-DB7ADDA1-C0AF-4467-AB2C-37619E30A1FC

P356

J.1440-1827.2008.02319.X

P1433

Pathology International

P1476

L-type amino-acid transporter ...... malignancy in prostate cancer.

@en

P2093

Akinori Ueno

http://www.w3.org/2001/XMLSchema#string

Golam Ferdous

http://www.w3.org/2001/XMLSchema#string

Hitoshi Endou

http://www.w3.org/2001/XMLSchema#string

Isao Okayasu

http://www.w3.org/2001/XMLSchema#string

Shiro Baba

http://www.w3.org/2001/XMLSchema#string

Takefumi Satoh

http://www.w3.org/2001/XMLSchema#string

Takeshi Sakata

http://www.w3.org/2001/XMLSchema#string

Tomoko Muto

http://www.w3.org/2001/XMLSchema#string

Tomoko Tsuruta

http://www.w3.org/2001/XMLSchema#string

Yoshikatsu Kanai

http://www.w3.org/2001/XMLSchema#string

P2860

Offering a treatment choice in the irradiation of prostate cancer leads to better informed and more active patients, without harm to well-being.

P304

7-18

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1440-1827.2008.02319.X

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19121087

http://www.w3.org/2001/XMLSchema#string

P921